secwatch.observer — SEC 8-K summary
======================================

Issuer:     KINGSWAY FINANCIAL SERVICES INC (KFS)
CIK:        0001072627
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0001437749-23-028717
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kingsway signs $7.9M deal to acquire 95% of National Institute of Clinical Research (NICR)
--------------------------------------------------------------------------------

- Total cash consideration $7,932,500 for 95% membership interest; $1M placed into escrow.
- NICR had $6.6M revenue and $1.2M adjusted EBITDA for TTM ending June 30, 2023 (unaudited).
- Purchase price implies 6.9x trailing adjusted EBITDA.
- Closing expected before end of Kingsway's fiscal first quarter ending March 31, 2024.
- Dr. Davide Zanchi to become CEO of NICR after close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1072627/000143774923028717/0001437749-23-028717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1072627/000143774923028717/kfs20231020_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-028717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer